Pharmasynthez has submitted an application for registration of Viconavir, a drug based on a combination of nirmatrelvir/ritonavir as active ingredients. The information on the fact can be found in the State Register of Medicines.
The dosage form in which the drug is registered is a film-coated tablet, 150 mg + 100 mg.
Nirmatrelvir + ritonavir are components of Pfizer’s Paxlovid drug.
In December 2021, the US Food and Drug Administration (FDA) issued a permit for the emergency use of Pfizer’s oral therapy for COVID-19.
